Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
53.08(c) 52.52(c) 53.11(c) 53.12(c) 52.61(c) Last
349 612 449 401 262 173 165 006 208 108 Volume
-0.23% -1.06% +1.12% +0.02% -0.96% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 529 M - -
Net income 2021 67,4 M - -
Net cash position 2021 375 M - -
P/E ratio 2021 34,1x
Yield 2021 -
Sales 2022 680 M - -
Net income 2022 114 M - -
Net cash position 2022 520 M - -
P/E ratio 2022 20,9x
Yield 2022 -
Capitalization 2 339 M 2 339 M -
EV / Sales 2021 3,71x
EV / Sales 2022 2,67x
Nbr of Employees 624
Free-Float 99,1%
More Financials
Company
Pacira BioSciences, Inc. is the holding company of Pacira Pharmaceuticals, Inc. The Company is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of... 
Sector
Pharmaceuticals
Calendar
11/04Earnings Release
More about the company
Ratings of Pacira BioSciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about PACIRA BIOSCIENCES, INC.
10/18PACIRA BIOSCIENCES : Needham Adjusts Pacira BioSciences' Price Target to $84 from $80, Kee..
MT
10/12PACIRA BIOSCIENCES : BMO Capital Lowers Pacira BioSciences' PT to $60 from $66, Keeps Mark..
MT
10/12PACIRA BIOSCIENCES : HC Wainwright Adjusts Pacira BioSciences' PT to $80 from $84, Keeps B..
MT
10/12PACIRA BIOSCIENCES : to Acquire Flexion Therapeutics Further Expanding Leadership Position..
PU
10/12PACIRA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Results of Operatio..
AQ
10/11SHAREHOLDER ALERT : WeissLaw LLP Investigates Flexion Therapeutics, Inc.
PR
10/11ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc..
PR
10/11Health Care Stocks Sliding in Late Monday Trading
MT
10/11Top Midday Gainers
MT
10/11Health Care Stocks Trade Lower Premarket Monday
MT
10/11Wall Street Declines on Soaring Energy Prices
MT
10/11FLEXION THERAPEUTICS : Agrees to Be Acquired by Pacira BioSciences; Shares Soar Pre-Bell
MT
10/11Top Premarket Gainers
MT
10/11PACIRA BIOSCIENCES : adds non-opioid pain drugs with $427.5 million Flexion buy
RE
10/11PACIRA BIOSCIENCES : to buy Flexion for $427.5 million
RE
More news
News in other languages on PACIRA BIOSCIENCES, INC.
10/11Les actions du secteur de la santé en baisse lundi en fin de journée
10/11Flexion Therapeutics accepte d'être rachetée par Pacira BioSciences ; les actions s'env..
10/11Pacira achète Flexion pour 427,5 millions de dollars
10/11Pacira achète Flexion pour 427,5 millions de dollars
10/04Les actions du secteur de la santé glissent cet après-midi
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | PCRX | US6951271005 | MarketScreener
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 52,61 $
Average target price 79,75 $
Spread / Average Target 51,6%
EPS Revisions
Managers and Directors
David M. Stack Chairman, Chief Executive & Operating Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Chief Technical Officer
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.-12.08%2 339
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979